Olaparib trial for rare pancreatic cancer ends early
NCT ID NCT05286827
First seen Apr 09, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study tested the cancer drug olaparib in people with a rare type of pancreatic cancer called pancreatic acinar cell carcinoma (PACC). The goal was to see if olaparib could shrink tumors or stop them from growing. Only 5 adults whose cancer had not responded to prior treatment or could not be removed by surgery were enrolled. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ACINAR CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.